Immunotherapy Using HLA-A24-restricted Survivin-derived Peptide for Patients with Colorectal Cancer and Breast Cancer

ABSTRACT: Interventions: Survivin-2B peptide vaccination at a dose of 0.1mg every 2 weeks Survivin-2B peptide vaccination at a dose of 1.0mg every 2 weeks Survivin-2B peptide vaccination at a dose of 10mg every 2 weeks Primary outcome(s): Evaluation of adverse effect Study Design: Parallel Non-randomized

DISEASE(S): Advanced Or Recurrent Colorectal Cancer And Breast Cancer

PROVIDER: 2616404 | ecrin-mdr-crc |

REPOSITORIES: ECRIN MDR